References to support the NCCN poster presentation
1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 4.2022. 2022 June 21; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
2. Mitin T, Kubicky CD. The Use of Hypofractionated Whole Breast Irradiation in Treatment of Patients With Early-Stage Breast Cancer in the United States. JAMA Oncol. 2015;1(2):245–246.
3. Niska JR, Keole SR, et al. Choosing wisely after publication of level I evidence in breast cancer radiotherapy. Breast Cancer (Dove Med Press). 2018 Feb 9;10:31-37.
4. Bekelman JE, Sylwestrzak G, Barron J, et al. Uptake and Costs of Hypofractionated vs Conventional Whole Breast Irradiation After Breast Conserving Surgery in the United States, 2008–2013. JAMA. 2014;312(23):2542–2550.
5. Jagsi R, Falchook AD, et al. Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials. International Journal of Radiation Oncology*Biology*Physics, Volume 90, Issue 5, 2014, 1001-1009.
6. Kang MM, Hasan Y, et al. Has Hypofractionated Whole-Breast Radiation Therapy Become the Standard of Care in the United States? An Updated Report from National Cancer Database, Clinical Breast Cancer, Volume 22, Issue 1, 2022, Pages e8-e20,
7. Rodríguez-Lopéz JL, Ling DC, et al. Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap? Journal of Oncology Practice 15, no. 3 (March 01, 2019) e195-e201.
Ganju RG, TenNapel M, et al. Impact of Peer Review on Use of Hypofractionated Regimens for Early-Stage Breast Cancer for Patients at a Tertiary Care Academic Medical Center and Its Community-Based Affiliates. Journal of Oncology Practice 2019 15:2
